Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOLAIR vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.
AEROLONE is not a recognized drug; no standard dosing available.
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by N-demethylation and oxidation. Approximately 10% excreted unchanged in urine.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
40% bound, primarily to albumin
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.45 L/kg; approximates total body water; higher in infants
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral: 96% (immediate release); sustained release: 80-100%
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
GFR < 30 m L/min: reduce dose by 50% and monitor serum levels. GFR 30-50 m L/min: reduce dose by 25%.
No data; not applicable.
Child-Pugh Class B: reduce dose by 50%. Class C: reduce dose by 75% or use alternative.
No data; not applicable.
Children 1-9 years: starting dose 10-16 mg/kg/day orally in divided doses every 4-6 hours; max 600 mg/day. Children 9-16 years: 10-16 mg/kg/day; max 800 mg/day. Adjust based on serum levels (5-15 mcg/m L).
No data; not applicable.
Start at lower end of dosing range (300 mg/day), titrate slowly with close monitoring of serum levels due to decreased clearance.
No data; not applicable.
No FDA black box warning.
None
Narrow therapeutic index; monitor serum theophylline levels to avoid toxicity.,Risk of serious cardiovascular events (e.g., arrhythmias, seizures) at high serum concentrations.,May exacerbate peptic ulcer disease.,Use caution in patients with hypoxemia, hypertension, or heart failure.,Drug interactions: cimetidine, fluoroquinolones, macrolides, and other CYP450 inhibitors increase levels; phenytoin, rifampin, and smoking decrease levels.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component of the formulation,Active peptic ulcer disease,Uncontrolled seizure disorders
Hypersensitivity to arformoterol or any component of the formulation
Dietary changes that affect CYP1A2 activity alter theophylline clearance. High-protein, low-carbohydrate diets increase clearance; high-carbohydrate, low-protein diets decrease clearance. Charcoal-broiled meats and cruciferous vegetables (e.g., broccoli, cabbage) induce metabolism, reducing efficacy. Caffeine-containing foods and beverages can potentiate toxicity and should be limited. Consistent dietary habits are critical to maintain stable serum levels.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of congenital anomalies cannot be excluded. First trimester: No consistent evidence of teratogenicity; some studies suggest possible association with cardiac defects. Second/third trimester: May cause fetal tachycardia, irritability, and jitteriness due to transplacental passage; neonatal withdrawal symptoms possible. Avoid use near term if possible.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.72. Concentrations in milk are about 60% of maternal serum. Breastfeeding is generally considered safe if maternal levels are therapeutic; however, irritability and insomnia in infants have been reported. Monitor infant for signs of caffeine-like effects. Use with caution, especially in preterm infants.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Pregnancy may decrease theophylline clearance by about 30% due to reduced protein binding and increased volume of distribution, but changes can vary. Dose adjustments should be guided by serum level monitoring. Typical starting dose: 400 mg/day oral, titrated to levels 5–15 mcg/m L. Increased doses may be needed in later pregnancy due to altered pharmacokinetics. Postpartum, clearance may increase, requiring dose reduction.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Theophylline (THEOLAIR) has a narrow therapeutic index (5-15 mg/L). Monitor serum levels due to inter- and intra-patient variability. Coadministration with CYP1A2 inhibitors (e.g., cimetidine, fluoroquinolones) or inducers (e.g., phenytoin, smoking) requires dose adjustments. Use with caution in patients with hepatic impairment, congestive heart failure, or fever, as clearance is reduced.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not double the dose if missed.,Avoid changes in smoking habits, diet, or new medications without consulting your doctor.,Report nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Do not consume large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects.,Maintain consistent intake of high-protein or low-protein diets.,Store at room temperature away from moisture and heat.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOLAIR vs AEROLONE, answered by our medical review team.
THEOLAIR is a Bronchodilator that works by Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular c AMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOLAIR and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOLAIR is: Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/m L. Maintenance: 400-600 mg/day in divided doses.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOLAIR and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOLAIR is classified as Category C. Theophylline (active ingredient in THEOLAIR) is classified as FDA Pregnancy Category C. Human data do not indicate a major teratogenic risk; however, a small increased risk of cong. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.